Key result
Infusion of protease-resistant IGFBP-4 inhibited lesion development by 53.3 +/- 6.1% in a hypercholesterolemic porcine model of neointimal hyperplasia.
Why the study?
Does infusion of a protease-resistant form of IGFBP-4 inhibit neointimal expansion in a porcine model of neointimal hyperplasia?
Does infusion of a protease-resistant form of IGFBP-4 inhibit neointimal expansion in a porcine model of neointimal hyperplasia?
Inhibiting IGFBP-4 proteolysis in the lesion microenvironment attenuates neointimal expansion in a porcine model, suggesting a potential therapeutic target for atherosclerosis or restenosis.
Answers are grounded in this paper and cite their sources.
Supports preclinical testing of IGFBP-4 in atherosclerosis models; leaves open translation to human cardiovascular therapy.
IGF-I has been shown to play a role in the progression of atherosclerosis in experimental animal models. IGF-binding protein-4 (IGFBP-4) binds to IGF-I and prevents its association with receptors. Overexpression of a protease-resistant form of IGFBP-4 has been shown to inhibit the ability of IGF-I to stimulate normal smooth muscle cell growth in mice. Based on these observations, we prepared a protease-resistant form of IGFBP-4 and infused it into hypercholesterolemic pigs. Infusion of the protease-resistant mutant inhibited lesion development by 53.3 +/- 6.1% (n = 6; P < 0.01). Control vessels that received an equimolar concentration of IGF-I and the protease-resistant IGFBP-4 showed no reduction in lesion size compared with control lesions that were infused with vehicle. Infusion of a nonmutated form of IGFBP-4 did not significantly inhibit lesion development. Proliferating cell nuclear antigen analysis showed that the mutant IGFBP-4 appeared to inhibit cell proliferation. The area occupied by extracellular matrix was also reduced proportionally compared with total lesion area. Immunoblotting revealed that the mutant IGFBP-4 remained intact, whereas the wild-type IGFBP-4 that was infused was proteolytically cleaved. Further analysis of the lesions revealed that a marker protein, IGFBP-5, whose synthesis is stimulated by IGF-I, was decreased in the lesions that received the protease-resistant, IGFBP-4 mutant, whereas there was no change in lesions that received wild-type IGFBP-4 or the mutant protein plus IGF-I. These findings clearly illustrate that infusion of protease-resistant IGFBP-4 into the perilesion environment results in inhibition of cell proliferation and attenuation of the development of neointima. The findings support the hypothesis that inhibiting IGFBP-4 proteolysis in the lesion microenvironment could be an effective means for regulating neointimal expansion.
No takes yet. Share an insight, caveat, or question.
Nichols et al. (2007) studied Neointimal hyperplasia (n=6). Protease-resistant IGFBP-4 vs. Vehicle or wild-type IGFBP-4 was evaluated on Lesion development (53.3 +/- 6.1% inhibition, p=< 0.01). Infusion of protease-resistant IGFBP-4 inhibited lesion development by 53.3 +/- 6.1% in a hypercholesterolemic porcine model of neointimal hyperplasia.
Synapse has enriched 10 related papers. Consider them for comparative context: